Arunachal Pradesh Headlines

Pulmonary Arterial Hypertension (PAH) Market Insights, Epidemiology, and Market Forecast 2030

 Breaking News
  • No posts were found

Pulmonary Arterial Hypertension (PAH) Market Insights, Epidemiology, and Market Forecast 2030

March 24
15:58 2020
Pulmonary Arterial Hypertension (PAH) Market Insights, Epidemiology, and Market Forecast 2030
DelveInsight’s “Pulmonary Arterial Hypertension (PAH) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Pulmonary Arterial Hypertension (PAH) , historical and forecasted epidemiology as well as the Pulmonary Arterial Hypertension (PAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

(Albany, US) DelveInsight launched its new report on Pulmonary Arterial Hypertension (PAH) – Market Insights, Epidemiology, and Market Forecast-2030

DelveInsight’s “Pulmonary Arterial Hypertension (PAH) – Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Pulmonary Arterial Hypertension (PAH) , historical and forecasted epidemiology as well as the Pulmonary Arterial Hypertension (PAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the report:
1. Pulmonary Arterial Hypertension (PAH) prevalence was observed to be 109 per million individuals among the population of fewer than 65 years old.
2. Around 16.2% of patients are newly diagnosed with Pulmonary Arterial Hypertension.
3. The overall prevalence of Pulmonary Hypertension was found to be 19.2 cases per Million Adult Inhabitants (MAI) among the Spanish population.

Key benefits of the report:
1. Pulmonary Arterial Hypertension market report covers a descriptive overview and comprehensive insight of the Pulmonary Arterial Hypertension Epidemiology and Pulmonary Arterial Hypertension market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Pulmonary Arterial Hypertension market report provides insights into the current and emerging therapies.
3. Pulmonary Arterial Hypertension market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Pulmonary Arterial Hypertension market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Pulmonary Arterial Hypertension market.

Download free sample pages: https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pah-market

“In 2017 the total prevalent cases of Pulmonary Arterial Hypertension were 70,774 in the seven major markets.”

The key players in Pulmonary Arterial Hypertension market are:
1. United Therapeutics
2. Liquidia Technologies
3. Reata Pharmaceuticals
4. Altavant Sciences
5. Acceleron Pharma

The launch of the emerging therapies is expected to significantly impact Pulmonary Arterial Hypertension treatment scenario in the upcoming years:-
Drugs covered:
1. Aurora-GT
2. Ralinepag
3. Bardoxolone Methyl
4. Rodatristat Ethyl
5. Sotatercept

Table of contents:

1. Key Insights
2. Executive Summary of Pulmonary Arterial Hypertension
3. SWOT Analysis of Pulmonary Arterial Hypertension
4. Pulmonary Arterial Hypertension Market Overview at a Glance
5. Pulmonary Arterial Hypertension Disease Background and Overview
6. Pulmonary Arterial Hypertension Epidemiology and Patient Population
7. Country Wise-Epidemiology of Pulmonary Arterial Hypertension (PAH)
7.1. The United States
7.2. Germany
7.3. France
7.4. Italy
7.5. Spain
7.6. The United Kingdom
7.7. Japan
8. Pulmonary Arterial Hypertension Treatment Algorithm
9. Unmet Needs
10. Case Studies
11. Organizations related to Pulmonary Arterial Hypertension
12. Pulmonary Arterial Hypertension Marketed Drugs
12.1.Approval and Market Presence
13. Pulmonary Arterial Hypertension Marketed Drugs by Companies
13.1.United Therapeutics Corporation
13.2.Johnson & Johnson
13.3.GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc.
13.4.Bayer AG
13.5. Pfizer
14. Safety and Efficacy of Marketed Drugs
15. Pulmonary Arterial Hypertension Emerging Therapies
15.1. Emerging Drugs Analysis
15.2.Aurora-GT: United Therapeutics
15.3.Ralinepag: United Therapeutics
15.5.Bardoxolone Methyl: Reata Pharmaceuticals
15.6.Rodatristat Ethyl: Altavant Sciences
15.7. Sotatercept: Acceleron Pharma
15.8. PB1064: PhaseBio Pharmaceuticals
15.9. CXA-10: Complexa
16. Other Promising Candidates
16.1. Inhaled Nitric Oxide: Bellerophon Pulse Technologies
16.2.RT234: Respira Therapeutics
17. Pulmonary Arterial Hypertension 7 Major Market Analysis
18. United States
19. EU5 Countries
19.1.Germany
19.2. France
19.3. Italy
19.4. Spain
19.5.United Kingdom
20. Japan
21. Market Drivers
22. Market Barriers
23. Appendix
24. DelveInsight Capabilities
25. Disclaimer
26. About DelveInsight

Download free report on Pulmonary Arterial Hypertension @https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pah-market

Related reports:

Pulmonary Arterial Hypertension – Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

Persistent Pulmonary Hypertension of the Newborn – Market Insights, Epidemiology, and Market Forecast-2030

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles